Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients.

ABSTRACT:

Background

The standard treatment for esthesioneuroblastoma, a rare malignant nasal vault neoplasm, is not established.

Methods

We retrospectively assessed the clinicopathological features, prognostic factors and treatment methods for 187 patients with esthesioneuroblastoma treated in China between 1981 and 2015. Overall survival (OS) and disease-free survival (DFS) were evaluated using the Kaplan-Meier method and log-rank tests.

Results

Twenty-three (12.3%), 48 (25.7%) and 113 (60.4%) patients had Kadish stage A, B and C esthesioneuroblastoma; 3 (1.6%) had unknown stage. Overall, 117 (62.6%) patients received surgery and combined radiotherapy with or without chemotherapy; 35 (18.7%) received radiotherapy with or without chemotherapy; 32 (17.1%) received surgery alone

SUBMITTER: Xiong L 

PROVIDER: S-EPMC5387340 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature